Pharming
Dutch biopharma firm Pharming was granted US FDA approval for Ruconest last night, just days after rumours of a negative decision prompted a 37% plummet in the firm’s share price.
The approval – which covers use of Ruconest to treat acute angioedema attacks in patients with hereditary angioedema (HAE) – will see Pharming’s partner Salix sell the drug in the US. The drug was cleared in Europe in 2010.
